These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27648969)

  • 1. Treatment With Recombinant Human Insulin-Like Growth Factor-1 Improves Growth in Patients With PAPP-A2 Deficiency.
    Muñoz-Calvo MT; Barrios V; Pozo J; Chowen JA; Martos-Moreno GÁ; Hawkins F; Dauber A; Domené HM; Yakar S; Rosenfeld RG; Pérez-Jurado LA; Oxvig C; Frystyk J; Argente J
    J Clin Endocrinol Metab; 2016 Nov; 101(11):3879-3883. PubMed ID: 27648969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult height and long-term outcomes after rhIGF-1 therapy in two patients with PAPP-A2 deficiency.
    Martín-Rivada Á; Barrios V; Martínez Díaz-Guerra G; Pozo J; Martos-Moreno GÁ; Argente J
    Growth Horm IGF Res; 2021; 60-61():101419. PubMed ID: 34358737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of IGF-1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density.
    Cabrera-Salcedo C; Mizuno T; Tyzinski L; Andrew M; Vinks AA; Frystyk J; Wasserman H; Gordon CM; Hwa V; Backeljauw P; Dauber A
    J Clin Endocrinol Metab; 2017 Dec; 102(12):4568-4577. PubMed ID: 29029190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomics changes in patients with PAPP-A2 deficiency in response to rhIGF1 treatment.
    Mastrangelo A; Martos-Moreno GÁ; Rupérez FJ; Chowen JA; Barbas C; Argente J
    Growth Horm IGF Res; 2018; 42-43():28-31. PubMed ID: 30119035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Modulators of the Growth Hormone - Insulin-Like Growth Factor Axis: Pregnancy-Associated Plasma Protein-A2 and Stanniocalcin-2.
    Fujimoto M; Hwa V; Dauber A
    J Clin Res Pediatr Endocrinol; 2017 Dec; 9(Suppl 2):1-8. PubMed ID: 29280739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rhIGF-1 Treatment Increases Bone Mineral Density and Trabecular Bone Structure in Children with PAPP-A2 Deficiency.
    Hawkins-Carranza FG; Muñoz-Calvo MT; Martos-Moreno GÁ; Allo-Miguel G; Del Río L; Pozo J; Chowen JA; Pérez-Jurado LA; Argente J
    Horm Res Paediatr; 2018; 89(3):200-204. PubMed ID: 29455208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disorders caused by genetic defects associated with GH-dependent genes: PAPPA2 defects.
    Fujimoto M; Andrew M; Dauber A
    Mol Cell Endocrinol; 2020 Dec; 518():110967. PubMed ID: 32739295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short stature with low insulin-like growth factor 1 availability due to pregnancy-associated plasma protein A2 deficiency in a Saudi family.
    Babiker A; Al Noaim K; Al Swaid A; Alfadhel M; Deeb A; Martín-Rivada Á; Barrios V; Pérez-Jurado LA; Alfares A; Al Alwan I; Argente J
    Clin Genet; 2021 Nov; 100(5):601-606. PubMed ID: 34272725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in pregnancy-associated plasma protein A2 cause short stature due to low IGF-I availability.
    Dauber A; Muñoz-Calvo MT; Barrios V; Domené HM; Kloverpris S; Serra-Juhé C; Desikan V; Pozo J; Muzumdar R; Martos-Moreno GÁ; Hawkins F; Jasper HG; Conover CA; Frystyk J; Yakar S; Hwa V; Chowen JA; Oxvig C; Rosenfeld RG; Pérez-Jurado LA; Argente J
    EMBO Mol Med; 2016 Apr; 8(4):363-74. PubMed ID: 26902202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-Year Therapy with Recombinant Human Insulin-Like Growth Factor-1 in a Patient with PAPP-A2 Deficiency.
    Muthuvel G; Dauber A; Alexandrou E; Tyzinski L; Andrew M; Hwa V; Backeljauw P
    Horm Res Paediatr; 2023; 96(5):449-457. PubMed ID: 36646053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human insulin-like growth factor-I therapy for children with growth disorders.
    Richmond EJ; Rogol AD
    Adv Ther; 2008 Dec; 25(12):1276-87. PubMed ID: 19066756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthropometric and biochemical correlates of PAPP-A2, free IGF-I, and IGFBP-3 in childhood.
    Fujimoto M; Khoury JC; Khoury PR; Kalra B; Kumar A; Sluss P; Oxvig C; Hwa V; Dauber A
    Eur J Endocrinol; 2020 Mar; 182(3):363-374. PubMed ID: 31961798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation - first three years of Polish experience.
    Petriczko E; Jackowski T; Horodnicka-Józwa A; Wikiera B; Noczyńska A; Korpal-Szczyrska M; Birkholz-Walerzak D; Małecka-Tendera E; Kalina-Fraska B; Kalina M; Barg E; Beń-Skowronek I; Szewczyk L; Hilczer M; Smyczyńska J; Stawerska R; Lewiński A; Ziora K; Bossowski A; Pietrewicz E; Pyrżak B; Kędzia A; Szalecki M; Kilian A; Walczak M
    Endokrynol Pol; 2019; 70(1):20-27. PubMed ID: 30351442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of recombinant human insulin-like growth factor-I in treating children with short stature.
    Collett-Solberg PF; Misra M;
    J Clin Endocrinol Metab; 2008 Jan; 93(1):10-8. PubMed ID: 18165284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I (rhIGF-I) therapy of short stature.
    Rosenbloom AL
    J Pediatr Endocrinol Metab; 2008 Apr; 21(4):301-15. PubMed ID: 18556960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study.
    Boonen S; Rosen C; Bouillon R; Sommer A; McKay M; Rosen D; Adams S; Broos P; Lenaerts J; Raus J; Vanderschueren D; Geusens P
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1593-9. PubMed ID: 11932288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mecasermin (recombinant human insulin-like growth factor I).
    Rosenbloom AL
    Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo responses to short-term recombinant human insulin-like growth factor-1 (IGF-I) in a severely growth-retarded girl with ring chromosome 15 and deletion of a single allele for the type 1 IGF receptor gene.
    de Lacerda L; Carvalho JA; Stannard B; Werner H; Boguszewski MC; Sandrini R; Malozowski SN; Leroith D; Underwood LE
    Clin Endocrinol (Oxf); 1999 Nov; 51(5):541-50. PubMed ID: 10594514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.